Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Psychological outcomes of dementia risk estimation in MCI patients: Results from the PreDADQoL project

Title: Psychological outcomes of dementia risk estimation in MCI patients: Results from the PreDADQoL project
Authors: Rostamzadeh, Ayda; Kalthegener, Franziska; Schwegler, Carolin; Romotzky, Vanessa; Gil-Navarro, Silvia; Rosende-Roca, Maitée; Ortega, Gemma; Canabate, Pilar; Moreno, Mariola; Maier, Franziska; Zeyen, Philip; Schild, Ann-Katrin; Meiberth, Dix; Sannemann, Lena; Bohr, Lara; Schmitz-Luhn, Björn; Boada, Mercè; Woopen, Christiane; Jessen, Frank
Source: Alzheimer's & Dementia ; 20 ; 11 ; 7635-7656
Publisher Information: USA
Publication Year: 2025
Collection: SSOAR - Social Science Open Access Repository
Subject Terms: Medizin und Gesundheit; Medicine and health; Alzheimer's disease; biomarker; close other; dementia risk; disclosure; mild cognitive impairment; satisfaction with life; Deutsche Version der Positive and Negative Affect Schedule PANAS (GESIS Panel) (ZIS 242; doi:10.6102/zis242); Medizin; Sozialmedizin; Medicine; Social Medicine; Demenz; Depression; Lebensqualität; Angst; Beratung; Problembewältigung; dementia; quality of life; anxiety; counseling; coping
Description: Introduction: Understanding the impact of biomarker-based dementia risk estimation in people with mild cognitive impairment (MCI) and their care partners is critical for patient care. Methods: MCI patients and study partners were counseled on Alzheimer's disease (AD) biomarker and dementia risk was disclosed. Data on mood, quality of life (QoL), and satisfaction with life (SwL) were obtained 1 week and 3 months after disclosure. Results: Seventy-five dyads were enrolled, and two-thirds of the patients opted for biomarker testing. None of the participants experienced clinically relevant depression or anxiety after disclosure. All dyads reported moderate to high QoL and SwL throughout the study. Patients reported more subthreshold depressive symptoms 1 week and lower QoL and SwL 3 months after disclosure. In patients, depression (odds ratio OR: 0.76) and anxiety (OR: 0.81) were significant predictors for the decision against biomarker testing. Discussion: No major psychological harm is to be expected in MCI patients and care partners after dementia risk disclosure.
Document Type: article in journal/newspaper
Language: unknown
Relation: https://www.ssoar.info/ssoar/handle/document/103415; https://doi.org/10.1002/alz.14226
DOI: 10.1002/alz.14226
Availability: https://www.ssoar.info/ssoar/handle/document/103415; http://nbn-resolving.org/urn:nbn:de:0168-ssoar-103415-3; https://doi.org/10.1002/alz.14226
Rights: Creative Commons - Namensnennung, Nicht kommerz., Keine Bearbeitung 4.0 ; Creative Commons - Attribution-Noncommercial-No Derivative Works 4.0
Accession Number: edsbas.3CF2E74E
Database: BASE